Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Teva Pharmaceutical Industries Ltd (TEVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 17,856,412
  • Shares Outstanding, K 1,016,880
  • Annual Sales, $ 22,385 M
  • Annual Income, $ -16,265,000 K
  • 36-Month Beta 0.67
  • Price/Sales 0.81
  • Price/Cash Flow 2.85
  • Price/Book 1.20

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.35 +5.63%
on 04/02/18
18.42 -6.22%
on 04/12/18
+0.36 (+2.13%)
since 03/23/18
3-Month
16.35 +5.63%
on 04/02/18
21.84 -20.92%
on 01/29/18
-3.89 (-18.38%)
since 01/25/18
52-Week
10.85 +59.17%
on 11/02/17
33.82 -48.94%
on 07/13/17
-13.49 (-43.86%)
since 04/25/17

Most Recent Stories

More News
Teva to Report First Quarter 2018 Financial Results on May 3, 2018

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its first quarter 2018 financial results on Thursday, May 3, 2018 at 7:00 a.m. ET.

TEVA : 17.27 (-1.65%)
Novartis (NVS) Reports Encouraging Data on MS Candidate

Novartis (NVS) announces encouraging results from a phase III study, EXPAND, on siponimod (BAF312) in patients with secondary progressive multiple sclerosis.

CELG : 89.20 (+0.07%)
NVS : 76.42 (-0.74%)
TEVA : 17.27 (-1.65%)
BIIB : 269.45 (+2.78%)
P&G Announces Third Quarter Earnings

The Procter & Gamble Company (NYSE:PG) reported third quarter fiscal year 2018 net sales of $16.3 billion, an increase of four percent versus the prior year. Organic sales increased one percent....

PG : 72.30 (-0.28%)
TEVA : 17.27 (-1.65%)
Teva and the Procter & Gamble Company Have Agreed to Terminate the PGT Healthcare Partnership

Teva Pharmaceutical Industries [NYSE and TASE: TEVA] has announced that Teva and the Procter & Gamble Company [NYSE: PG] have agreed to terminate the PGT Healthcare partnership that the two...

PG : 72.30 (-0.28%)
TEVA : 17.27 (-1.65%)
P&G Acquires the Consumer Health Business of Merck KGaA, Darmstadt, Germany

--Replaces and Improves Upon Successful PGT Healthcare Joint Venture

PG : 72.30 (-0.28%)
TEVA : 17.27 (-1.65%)
MKKGY : 19.8250 (-0.40%)
Amgen's Aimovig Reduces Episodic Migraine in 30% Patients

Amgen (AMGN) releases full data from the phase IIIb trial, evaluating the efficacy and safety of Aimovig on patients suffering episodic migraine with multiple treatment failures.

LLY : 81.14 (+1.31%)
NVS : 76.42 (-0.74%)
TEVA : 17.27 (-1.65%)
AMGN : 174.83 (+1.68%)
Teva to Present New Data Across Multiple Therapeutic Areas at 70th Annual Meeting of the American Academy of Neurology

--COPAXONE(R) (glatiramer acetate injection) and AUSTEDO(R) (deutetrabenazine) tablets data highlight Teva's ongoing clinical research

TEVA : 17.27 (-1.65%)
Mylan Inks Deal with Mapi Pharma for Multiple Sclerosis Drug

Mylan (MYL) has inked a deal with Israel based Mapi Pharma to acquire its multiple sclerosis candidate.

MYL : 38.94 (-3.25%)
MNTA : 19.60 (+0.26%)
TEVA : 17.27 (-1.65%)
RHHBY : 27.8300 (-0.32%)
Today's Research Reports on Stocks to Watch: Teva and Therapix

NEW YORK, NY / ACCESSWIRE / April 10, 2018 / Shares of Therapix were popping on Monday after positive trial results about the company's proprietary cannabinoid product platform THX-IIO fell upon the eyes...

TEVA : 17.27 (-1.65%)
Quotidian Technical Highlights on Selected Healthcare Stocks -- GlaxoSmithKline, Synergy Pharma, Teva Pharma, and Perrigo

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on GSK, SGYP, TEVA, and PRGO which can be accessed for free by signing up to www.wallstequities.com/registration....

TEVA : 17.27 (-1.65%)
SGYP : 1.59 (-4.22%)
GSK : 39.12 (-3.74%)
PRGO : 77.82 (-3.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended...

See More

Key Turning Points

2nd Resistance Point 17.89
1st Resistance Point 17.58
Last Price 17.27
1st Support Level 16.96
2nd Support Level 16.66

See More

52-Week High 33.82
Fibonacci 61.8% 25.05
Fibonacci 50% 22.33
Fibonacci 38.2% 19.62
Last Price 17.27
52-Week Low 10.85

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar